Mesoblast (MESO) Stock Price, Quote, News & History | Benzinga

Mesoblast Ltd (MESO) Stock Price, Quote, News & History

MESONASDAQ

Trade with Public

Trade with Public

$17.00

-0.43-2.47%

At close: Aug 21, 5:00 PM EST

$17.00

N/A

After Hours: 8:31 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$16.98

Close

$17.00

Volume / Avg.

164.75K / 221.71K

Day Range

$16.81 - $17.11

52 Wk Range

12.66 - 21.50

Market Cap

$2.20B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

58

Short Interest

3.35%

Days to Cover

11.06

Recent Mesoblast Limited News

Flowers Foods Posts Downbeat Q2 Results, Joins OSI Systems, Aveanna Healthcare And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

US stock futures rise, Dow up 150 points. Flowers Foods (NYSE:FLO) plunges on poor earnings & lowered forecast. Other stocks also down in pre-market.

Avi Kapoor

Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment

Mesoblast finished patient dosing in its Phase 3 trial for a cellular back pain treatment, targeting a market worth over $10 billion.

Vandana Singh

H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday

H World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers include ANGX, ARGX, and MESO.

Avi Kapoor

Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

U.S. stock futures mixed, Dow down 0.1%. Swarmer Inc (NASDAQ: SWMR) shares drop 7% after reporting worse-than-expected financial results.

Avi Kapoor

PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday

US stocks close higher, Dow Jones up 100 points, PayPal shares rise on $53 billion acquisition proposal, other big gains from Aehr Test, Electrovaya, Robo.ai, Falcon's Beyond, Veradermics, Lucid Group, Kopin, MINISO, Mesoblast, Nexstar, Lionsgate, Karman.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-

Investing Cash Flow (TTM)

-1.40M

Financing Cash Flow (TTM)

-10.46M

Free Cash Flow (TTM)

-52.52M

Capital Expenditure (TTM)

-1.33M

Net Change in Cash (TTM)

-63.05M

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.32B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

3.93

Earnings Yield % (TTM)

-

Earnings Yield % (FWD)

-2.43%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$4.43

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$73.95M

Total Cash

-

Debt to Equity

0.24

Issuance of Debt (TTM)

-$2.59M

Repayment of Debt (TTM)

-$73.95M

Key Statistics

Open

$16.98

Close

$17.00

Volume / Avg.

164.75K / 221.71K

Day Range

$16.81 - $17.11

52 Wk Range

12.66 - 21.50

Market Cap

$2.20B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

58

Short Interest

3.35%

Days to Cover

11.06

About

Sector

Health Care

Industry

Biotechnology

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates includ...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy Mesoblast (MESO) stock?

A

You can purchase shares of Mesoblast (NASDAQ:MESO) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Mesoblast (MESO) competitors?

A

Other companies in Mesoblast’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Mesoblast (MESO) stock?

A

Mesoblast has a consensus price target of $18.00.

Q

What is the current price for Mesoblast (MESO)?

A

The stock price for Mesoblast (NASDAQ: MESO) is $17 last updated August 21, 2026 at 8:31 AM EDT.

Q

Does Mesoblast (MESO) pay a dividend?

A

There are no upcoming dividends for Mesoblast.

Q

When is Mesoblast (NASDAQ:MESO) reporting earnings?

A

Mesoblast does not have any upcoming earnings scheduled.

Q

Is Mesoblast (MESO) going to split?

A

There is no upcoming split for Mesoblast.

Q

What sector and industry does Mesoblast (MESO) operate in?

A

Mesoblast is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.